NEW YORK, NY / ACCESSWIRE / May 13, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Healthcare Services Group, Inc. (NASDAQ: HCSG)
Class Period: April 11, 2017 to March 4, 2019
Lead Plaintiff Deadline: May 21, 2019
Healthcare Services Group, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) Defendant Wahl either knew or was reckless in not knowing that the Company had been accused of strategically rounding quarterly earnings per share, and therefore investors could not rely upon the Company's track record without conducting a thorough investigation into the allegations; (b) Defendants concealed that the SEC had written to the Company in November 2017 to inquire into the Company's earnings per share rounding practices; and (c) the Company concealed that the SEC delivered a subpoena to the Company in March 2018 demanding the Company produce documents in connection with how it calculated earnings per share.
Get additional information about the HCSG lawsuit: http://www.kleinstocklaw.com/pslra-1/healthcare-services-group-inc-loss-submission-form?id=1499&from=1
Care.com, Inc. (NYSE: CRCM)
Class Period: March 27, 2015 to April 1, 2019
Lead Plaintiff Deadline: June 3, 2019
The complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts, with respect to the manner in which the Company vets the caregivers and daycare providers listed on its website.
Get additional information about the CRCM lawsuit: http://www.kleinstocklaw.com/pslra-1/care-com-inc-loss-submission-form?id=1499&from=1
Apyx Medical Corporation (NASDAQ: APYX)
Class Period: August 1, 2018 to April 1, 2019
Lead Plaintiff Deadline: June 17, 2019
The lawsuit alleges that Apyx Medical Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (2) as a result, the clinical study did not support the Company's application for regulatory clearance; (3) as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Get additional information about the APYX lawsuit: http://www.kleinstocklaw.com/pslra-1/apyx-medical-corporation-loss-submission-form?id=1499&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm